 "Covid-19 crisis: Briton Pharma gets DCGI nod to launch favipiravir")
After Glenmark’s Fabiflu, a second favipiravir—an oral antiviral drug used in Covid-19 treatment—has got approval from the drugs regulator.
Pune-based Brinton Pharmaceuticals said on Thursday it had got the nod from the Drugs Controller General of India (DCGI) to market its brand Faviton, priced at Rs 59 per tablet.
Faviton will be available in a strip of 10 tablets and in a box of 50 tablets. It will be available in 200 mg tablets.
Brinton will also be exporting Faviton globally.
”Emerging favorable global clinical evidence suggests, Favipiravir is an effective treatment option in the management of mild to moderate Covid-19. As this is an orally administered medication, it is more convenient compared to intravenously administered medicines,” the company said in its statement.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%